Skip to main content
main-content

08.05.2019 | Original Paper | Ausgabe 2/2019

Acta Neuropathologica 2/2019

Mutational patterns and regulatory networks in epigenetic subgroups of meningioma

Zeitschrift:
Acta Neuropathologica > Ausgabe 2/2019
Autoren:
Nagarajan Paramasivam, Daniel Hübschmann, Umut H Toprak, Naveed Ishaque, Marian Neidert, Daniel Schrimpf, Damian Stichel, David Reuss, Philipp Sievers, Annekathrin Reinhardt, Annika K. Wefers, David T. W. Jones, Zuguang Gu, Johannes Werner, Sebastian Uhrig, Hans-Georg Wirsching, Matthias Schick, Melanie Bewerunge-Hudler, Katja Beck, Stephanie Brehmer, Steffi Urbschat, Marcel Seiz-Rosenhagen, Daniel Hänggi, Christel Herold-Mende, Ralf Ketter, Roland Eils, Zvi Ram, Stefan M. Pfister, Wolfgang Wick, Michael Weller, Rachel Grossmann, Andreas von Deimling, Matthias Schlesner, Felix Sahm
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00401-019-02008-w) contains supplementary material, which is available to authorized users.
Nagarajan Paramasivam, Daniel Hübschmann, Matthias Schlesner, and Felix Sahm shared first or shared last authorship.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

DNA methylation patterns delineate clinically relevant subgroups of meningioma. We previously established the six meningioma methylation classes (MC) benign 1–3, intermediate A and B, and malignant. Here, we set out to identify subgroup-specific mutational patterns and gene regulation. Whole genome sequencing was performed on 62 samples across all MCs and WHO grades from 62 patients with matched blood control, including 40 sporadic meningiomas and 22 meningiomas arising after radiation (Mrad). RNA sequencing was added for 18 of these cases and chromatin-immunoprecipitation for histone H3 lysine 27 acetylation (H3K27ac) followed by sequencing (ChIP-seq) for 16 samples. Besides the known mutations in meningioma, structural variants were found as the mechanism of NF2 inactivation in a small subset (5%) of sporadic meningiomas, similar to previous reports for Mrad. Aberrations of DMD were found to be enriched in MCs with NF2 mutations, and DMD was among the most differentially upregulated genes in NF2 mutant compared to NF2 wild-type cases. The mutational signature AC3, which has been associated with defects in homologous recombination repair (HRR), was detected in both sporadic meningioma and Mrad, but widely distributed across the genome in sporadic cases and enriched near genomic breakpoints in Mrad. Compared to the other MCs, the number of single nucleotide variants matching the AC3 pattern was significantly higher in the malignant MC, which also exhibited higher genomic instability, determined by the numbers of both large segments affected by copy number alterations and breakpoints between large segments. ChIP-seq analysis for H3K27ac revealed a specific activation of genes regulated by the transcription factor FOXM1 in the malignant MC. This analysis also revealed a super enhancer near the HOXD gene cluster in this MC, which, together with general upregulation of HOX genes in the malignant MC, indicates a role of HOX genes in meningioma aggressiveness. This data elucidates the biological mechanisms rendering different epigenetic subgroups of meningiomas, and suggests leveraging HRR as a novel therapeutic target.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (XLSX 10 kb)Online Resource 1: Supplementary Table 1 Cohort characteristics
401_2019_2008_MOESM1_ESM.xlsx
Supplementary material 2 (XLSX 138 kb)Online Resource 2: Supplementary Table 2 Functional exonic variants and small insertions/deletions.
401_2019_2008_MOESM2_ESM.xlsx
Supplementary material 3 (XLSX 6 kb)Online Resource 3: Supplementary Table 3 Association of methylation classes with functional exonic small variants
401_2019_2008_MOESM3_ESM.xlsx
Supplementary material 4 (PDF 394 kb)Online Resource 4: Supplementary Table 4 Quality control metrics of 16 ChIP-seq samples generated using the ChIPQC R package. Supplementary Figure 1 Volcano plot showing differential expression in NF2 mutant vs wild-type cases. Supplementary Figure 2 Mutational signature analysis (legend below figure). Supplementary Figure 3 Correlation between genomic instability and AC3 stratified for Mrad and sporadic cases. Supplementary Figure 4 HOX gene expression
401_2019_2008_MOESM4_ESM.pdf
Supplementary material 5 (CSV 15731 kb)Online Resource 5 Expression data from RNA sequencing from FFPE samples
401_2019_2008_MOESM5_ESM.csv
Supplementary material 6 (CSV 12660 kb)Online Resource 6 Expression data from RNA sequencing from frozen samples
401_2019_2008_MOESM6_ESM.csv
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2019

Acta Neuropathologica 2/2019 Zur Ausgabe
  1. Sie können e.Med Neurologie & Psychiatrie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Neurologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Pathologie

01.08.2019 | Originalien | Ausgabe 4/2019

Cocainkonsumintensität als Ursache erworbener Herzerkrankungen?

Korrelationen bei cocainassoziierten Drogentodesfällen

26.06.2019 | Nebennierentumoren | CME | Ausgabe 4/2019

CME: Aktualisierter Überblick zu Tumoren der Nebenniere

Aktualisierter Überblick

26.06.2019 | Schwerpunkt: Sarkome | Ausgabe 4/2019

Diagnostik und Management von Gefäßmalformationen

Interdisziplinäres Teamwork gefragt

26.06.2019 | Schwerpunkt: Sarkome | Ausgabe 4/2019

Systemische Therapie von Sarkomen

Neue Biomarker und Therapiestrategien